NCT05625594View on ClinicalTrials.gov

Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 29, 2023

Primary Completion Date

May 21, 2026

Study Completion Date

May 21, 2026

Conditions
Central Nervous System Lymphoma
Interventions
PROCEDURE

Aspiration

Undergo CSF aspiration

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Catheterization

Undergo catheterization

BIOLOGICAL

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes

Given ICV

PROCEDURE

Computed Tomography

Undergo CT

DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine

Given IV

PROCEDURE

Leukapheresis

Undergo leukapheresis

PROCEDURE

Lumbar Puncture

Undergo lumbar puncture

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Positron Emission Tomography

Undergo PET

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER